Image-Based Assessment and Clinical Significance of Absorbed Radiation Dose to Tumor in Repeated High-Dose ![]() |
Byun, Byung-Hyun
(Department of Nuclear Medicine, Korea Institute of Radiological and Medical Sciences)
Kim, Kyeong-Min (Lab. Of Nuclear Medicine Basic Research, Korea Institute of Radiological and Medical Sciences) Woo, Sang-Keun (Lab. Of Nuclear Medicine Basic Research, Korea Institute of Radiological and Medical Sciences) Choi, Tae-Hyun (Lab. Of Nuclear Medicine Basic Research, Korea Institute of Radiological and Medical Sciences) Kang, Hye-Jin (Department of Internal Medicine, Korea Institute of Radiological and Medical Sciences) Oh, Dong-Hyun (Department of Nuclear Medicine, Korea Institute of Radiological and Medical Sciences) Kim, Byeong-Il (Department of Nuclear Medicine, Korea Institute of Radiological and Medical Sciences) Cheon, Gi-Jeong (Department of Nuclear Medicine, Korea Institute of Radiological and Medical Sciences) Choi, Chang-Woon (Department of Nuclear Medicine, Korea Institute of Radiological and Medical Sciences) Lim, Sang-Moo (Department of Nuclear Medicine, Korea Institute of Radiological and Medical Sciences) |
1 | DeNardo GL, Juweid ME, White CA, Wiseman GA, DeNardo SJ. Role of dosimetry in radioimmunotherapy planning and treatment dosing. Critical Rev Oncol Hematol 2001;39:203-18 DOI ScienceOn |
2 |
Matthay KK, Panina C, Huberty J, Price D, Glidden DV, Tang HR, et al. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with |
3 | Moog F, Bangerter M, Diederichs CG, Guhlmann A, Kotzerke J, Merkle E, et al. Lymphoma: role of FDG-PET in nodal staging. Radiology 1997;203:795-800 DOI PUBMED ScienceOn |
4 |
Hong SP, Hahn JS, Lee JD, Bae SW, Youn MJ. $^{18}F-fluorodeoxyglucose-positron emission tomography in the staging of malignant lymphoma compared with CT and |
5 | Paulino AC, Johnstone PA. FDG-PET in radiotherapy treatment planning: Pandora's box? Int J Radiat Oncol Biol Phys 2004;59:4-5 DOI PUBMED ScienceOn |
6 | Erdi YE, Rosenzweig K, Erdi AK, Macapinlac HA, Hu YC, Braban LE, et al. Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiother Oncol 2002;62:51-60 DOI ScienceOn |
7 |
Wiseman GA, White CA, Stabin M, Dunn WL, Erwin W, Dahlbom M, et al. Phase I/II |
8 | Witzig TE, Flinn IW, Gordon LI, Vo K, Wiseman GA, Flinn IW, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory non-Hodgkin's lymphoma. J Clin Oncol 2002;20:3262-69 DOI ScienceOn |
9 |
Valkema R, Pauwels SA, Kvols LK, Kwekkeboom DJ, Jamar F, de Jong M, et al. Long-term follow-up of renal function after peptide receptor radiation therapy with |
10 | Liu A, Wiliams LE, Wong JYC, Williams LE, Liu A, Wilczynski S et al. Monte Carlo assisted voxel source kernal method (MAVSK) for internal dosimetry. J Nucl Med Biol 1998;25:423-33 DOI ScienceOn |
11 |
Ulaner GA, Colletti PM, Conti PS. B-cell non-Hodgkin's lymphoma: PET/CT evaluation after |
12 |
Giraud P, Grahek D, Montravers F, Carette MF, Deniaud-Alexandre E, Julia F, et al. CT and |
13 |
Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K, et al. |
14 | Bradley J, Thorstad WL, Mutic S, Miller TR, Dehdashti F, Siegel BA, et al. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004;59:78-86 DOI PUBMED ScienceOn |
15 |
Shah J, Wang W, Harrough VD, Saville W, Meredith R, Shen S, et al. Retreatment with |
16 |
Dewaraja YK, Wilderman SJ, Ljungberg M, Koral KF, Zasadny K, Kaminiski MS. Accurate dosimetry in |
17 | Yoriyaz H, Stabin MG, dos Santos A Monte Carlo MCNP-4B-hased absorbed dose distribution estimates for patient-specific dosimetry. J Nucl Med 2001;42:662 PUBMED ScienceOn |
18 |
Nestle U, Kremp S, Grosu AL. Practical integration of |
19 | Joyce JM, Degirmenci B, Jacobs S, McCook B, Avril N. FDG PET CT assessment of treatment response after 90y ibritwnomab tiuxetan radioimmunotherapy. Clin Nucl Med 2005;30:564-8 DOI ScienceOn |
20 | Schoder H, Erdi YE, Chao K, Gonen M, Larson SM, Yeung HW. Clinical implications of different image reconstruction parameters for interpretation of whole-body PET studies in cancer patients. J Nucl Med 2004;45:559-66 PUBMED ScienceOn |
21 | Carlo G, Kenneth R, Giuseppe LC. Current status of PET/CT for tumour volume definition in radiotherapy treatment planning for non-small cell lung cancer (NSCLC). Lung Cancer 2007;57:125-34 DOI ScienceOn |
22 | Virgolini I, Britton K, Buscornbe J, Moncayo R, Paganelli G, Riva P. In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med 2002;32:148-55 DOI ScienceOn |
23 |
Ljungberg M, Sjo'' green K, Liu X, Frey E, Dewaraja Y, Strand SE. A 3-dimensional absorbed dose calculation method based on quantitative SPECT for radionuclide therapy: evaluation for |
24 | DeNardo GL, Hartmann Siantar CL, DeNardo SJ. Radiation dosimetry for radionuclide therapy in a nonmyeloablative strategy. Cancer Biother Radiopharm 2002;17:107-18 DOI ScienceOn |
25 | Klaus B and Hubert MT. Accurate dosimetry: an essential step towards good clinical practice in nuclear medicine. Nucl Med Commun 2005;26:581-6 DOI ScienceOn |
26 | De Jong M, Kwekkeboom D, Valkema R, Krenning EP. Radiolabelled peptides for tumour therapy: current status and future directions-plenary lecture at the EANM 2002. Eur J Nucl Med Mol Imaging 2003;30:463-69 DOI PUBMED ScienceOn |
27 |
Kaminski MS, Zelenetz AD, Press OW, Saleh M, Leonard J, Fehrenbacher L. Pivotal study of iodine |
28 | Reubi JC, Ma''ke HR, Krenning EP. Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med 2005;46(Suppl 1):67S-75S PUBMED ScienceOn |
29 |
Bishton MJ, Leahy MF, Hicks RJ, Turner JH, McQuillan AD, Seymour JF. Repeat treatment with |
30 | Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, et al. An overview of the peptide receptor radionuclide therapy with 3 different radiolabeled somatostatin analogs. J Nucl Med 2005;46(Suppl 1):62S-6S PUBMED ScienceOn |
31 |
Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, et al. Whole body emission tomography using |
32 | Furhang EE, Chui CS, Sgouros G. A Monte Carlo approach to patient specific dosimetry. Med Phys 1996;23:1523 DOI ScienceOn |
33 |
Bodei L, Cremonesi M, Grana C, Rocca P, Bartolomei M, Chinol M, Paganelli G. Receptor radionuclide therapy with |
34 | Koral KF, Dewaraja Y, Clarke LA, Li J, Zasadny KR, Rommelfanger SG, et al. Tumor-absorbed-dose estimates versus response in tositumomab therapy of previously untreated patients with follicular non-Hodgkin's lymphoma; preliminary report. Cancer Biother Radiopharm 2000;15:301-3 DOI PUBMED ScienceOn |
35 |
Koral K, Francis I, Kroll S, Zasadny KR, Kaminski MS, Wahl RL. Volume reduction versus radiation dose for tumors in previously untreated lymphoma patients who received |
36 | Stumpe KD, Urbinelli M, Steinert HC, Glanzmann C, Buck A, von Schulthess GK Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Bur J Nucl Med 1998;25:721-8 DOI PUBMED ScienceOn |
37 |
Pauwels S, Barone R, Walrand S, Borson-Chazot F, Valkema R, Kvols LK, et al. Practical dosimetry of peptide receptor radionuclide therapy with |
38 |
Torizuka T, Zasadny KR, Kison PV, Rommelfanger SG, Kaminski MS, Wahl RL. Metabolic response of non-Hodgkin's lymphoma to |
39 |
Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA. Radiolabeled somatostatin analog [ |
40 |
Kaminski MS, Radford JA, Gregory SA, Leonard JP, Knox SJ, Kroll S et al. Re-treatment with |
![]() |